Solid TumorQUANTACTNCT04762862
QUANTACT : Impact of Pangenomic QUANTitative Alterations in Cancer Therapy
An observational study of Solid Tumor, run by Centre Hospitalier Universitaire de Nice at 1 site in France.
Trial summary
"Precision medicine and targeted therapies have played a crucial role over the past ten years in the personalized care of cancer patients. In this retrospective and observational study, we focused on patients for which no standard or curative treatment was available and for which the management was discussed in a… Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Solid Tumor
- How many people
- 1,200 participants
- Where
- 1 siteFrance
- Study dates
- 1 Feb 2021to 31 Dec 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Cancer patients for which no standard or curative treatment was available and for which the personalized management was discussed in a Molecular Tumor Board.
Who may be able to join
- Histologically or cytologically confirmed solid tumor malignancy that is advanced or metastatic ;
- no standard or curative treatment available;
- non-opposition of the patient collected.
Who cannot join
- multiple cancer patient;
- ECOG Scale of Performance Status (PS) ≥2
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
"Precision medicine and targeted therapies have played a crucial role over the past ten years in the personalized care of cancer patients. In this retrospective and observational study, we focused on patients for which no standard or curative treatment was available and for which the management was discussed in a Molecular Tumor Board (MTB).
The role of the MTB is to decide the most appropriate therapeutic options for patients according to the potential identification of molecular targets.
Read more
Among the analyses carried out, we focused on a quantitative genome-wide analysis: the CGH/SNP-array (Comparative Genomic Hybridization / Single Nucleotide Polymorphism on array). The objective was to evaluate the impact of CGH/SNP-array analyses in the identification of targeted molecular alterations.
"
- Conditions
- Solid Tumor
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of targeted molecular alterations
Number of targeted molecular alterations
Measured: at day 0
Secondary outcomes (1)
Number of patients eligible for targeted therapy (clinical trials or "off-label" drug)
Number of patients eligible for targeted therapy (clinical trials or "off-label" drug)
Measured: at day 0
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Feb 2021
- Study start1 Feb 2021
- Primary completion31 Aug 2026 (estimated)
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Solid TumorStudies of the same condition, open and under way.
- More trials run by Centre Hospitalier Universitaire de NiceThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 1,200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Centre Hospitalier Universitaire de Nice
- Sponsor type
- University, hospital or other
- Collaborators
- Centre Antoine Lacassagne
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04762862
- Sponsor's protocol ID
- 21LGTS01
- Acronym
- QUANTACT
- Status last verified
- Apr 2025
- First submitted
- 11 Feb 2021
- Last updated
- 10 Apr 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 10 Apr 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- QUANTACT : Impact of Pangenomic QUANTitative Alterations in Cancer Therapy
- ClinicalTrials.gov ID
- NCT04762862
- Acronym / sponsor ID
- QUANTACT / 21LGTS01
- Conditions
- Solid Tumor
- Study type
- Observational
- Recruitment status
- Enrolling by invitation
- Enrolment
- 1,200 participants (estimated)
- Lead sponsor
- Centre Hospitalier Universitaire de NiceUniversity, hospital or other
- Collaborators
- Centre Antoine Lacassagne
- Study start
- 1 Feb 2021 (actual)
- Primary completion
- 31 Aug 2026 (estimated)
- Study completion
- 31 Dec 2026 (estimated)
- First posted
- 21 Feb 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
"Precision medicine and targeted therapies have played a crucial role over the past ten years in the personalized care of cancer patients. In this retrospective and observational study, we focused on patients for which no standard or curative treatment was available and for which the management was discussed in a Molecular Tumor Board (MTB).
The role of the MTB is to decide the most appropriate therapeutic options for patients according to the potential identification of molecular targets.
Among the analyses carried out, we focused on a quantitative genome-wide analysis: the CGH/SNP-array (Comparative Genomic Hybridization / Single Nucleotide Polymorphism on array). The objective was to evaluate the impact of CGH/SNP-array analyses in the identification of targeted molecular alterations.
"
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Cancer patients for which no standard or curative treatment was available and for which the personalized management was discussed in a Molecular Tumor Board.
Key inclusion criteria (3 listed)
- Histologically or cytologically confirmed solid tumor malignancy that is advanced or metastatic ;
- no standard or curative treatment available;
- non-opposition of the patient collected.
Key exclusion criteria (2 listed)
- multiple cancer patient;
- ECOG Scale of Performance Status (PS) ≥2
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Number of targeted molecular alterations
Time frame: at day 0
Number of targeted molecular alterations
1 secondary outcome
Number of patients eligible for targeted therapy (clinical trials or "off-label" drug)
Time frame: at day 0
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Apr 2025.
- Individual participant dataSharing planned: No
Related trials for Solid Tumor
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
Active, not recruitingPhase 1
A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK043 in Patients With Advanced Solid Tumor
Neoplasms
Active, not recruitingPhase 3
A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial
Solid Tumors
RecruitingPhase 1
IL-12 Genetically Engineered Myeloid Cells in Participants With Relapsed, Refractory Solid Tumors
Relapsed Solid Tumor Malignancies, Refractory Solid Tumor Malignancies
RecruitingObservational study
Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
Malignant Solid Neoplasm
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Solid Tumor, run by Centre Hospitalier Universitaire de Nice at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 10 Apr 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of targeted molecular alterations (time frame: at day 0). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Apr 2025.